Physician profile
David De Angel Sola
NPI 1467707570
$1,620.95
in general payments reported to CMS, 2019-2025
12 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Sleep Medicine (Pediatrics) provider received nationally (typical 2025 total: $235).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $118 · 2021: $183 · 2022: $226 · 2023: $193 · 2024: $305 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.97 |
| Education | $234.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $446.54 | 2024-2025 | |
| Harmony Biosciences LLC | $327.36 | 2023-2025 | Wakix |
| Genzyme Corporation | $184.82 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $118.71 | 2022 | |
| Glaxosmithkline, LLC. | $117.79 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $109.64 | 2021-2024 | Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $109.04 | 2021 | |
| United Therapeutics Corporation | $76.55 | 2023 | Tyvaso |
| Merck Sharp & Dohme LLC | $45.00 | 2025 | Enflonsia |
| Mylan Specialty L.P. | $44.18 | 2024 | |
| Sobi, INC | $23.81 | 2022 | |
| Chiesi USA, INC. | $17.51 | 2024 | Curosurf |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David De Angel Sola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.